FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	mated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				' '										
1. Name and Address of Reporting Person*					2. Issuer Name <b>and</b> Ticker or Trading Symbol RHYTHM PHARMACEUTICALS, INC.										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Gottesa	Hestiletet ixetti ivitchaet					RYTM ]								١.	X	Direc	ctor		10% O	wner	
(Last)	/Eir	ret) (	Middle)											_	X	Office	er (give title w)		Other (	(specify	
					3. Date of Earliest Transaction (Month/Day/Year)												CEO and	and President			
500 BOYLSTON STREET, 11TH FLOOR				12/0	12/03/2018																
(Street)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)							
BOSTON	I M	Α (	)2116		1										X	Form	n filed by One	e Rep	orting Pers	on	
(City)	(St	ate) (	Zip)													orm filed by More than One Reporting erson					
		Tabl	e I - Non	-Deriva	ative	Sec	curitie	s Ac	quired,	Dis	posed o	f, oı	Ben	eficia	ally (	Owne	ed				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					ar)   E	A. Deemed xecution Date, any Month/Day/Year)		Code	Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3,			4 and Se Be Ov		Securities Beneficially		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	Amount (A		Price	Transa		action(s) 3 and 4)			(111511.4)	
Common	Stock			12/03	/2018	3			S <sup>(1)</sup>		563		D	D \$30 571,476 D							
		Та	able II - D								sed of, onvertib				y Ov	vned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (I 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)				vative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nur of	ount nber ires							

## Explanation of Responses:

1. On December 3, 2018, Mr. Gottesdiener sold 563 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

/s/ Keith M. Gottesdiener 12/06/2018

\*\* Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.